Skip to main content

Advertisement

SpringerLink
Log in

Melanoma Diagnosis and Treatment in the Elderly

  • Dermatology and Wound Care (C Sayed, Section Editor)
  • Published:
Current Geriatrics Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

While the overall incidence of melanoma has remained stable in younger populations, the rate of diagnosis in the elderly is rising. Diagnosis and treatment of melanoma presents a major public health challenge for providers, patients, and caretakers. In this paper, we address unique considerations for diagnosis and management of melanoma in the elderly population.

Recent Findings

There are clinically significant differences in the presentation of melanoma in the elderly. Diagnosis is often delayed, thus screening is crucial and should focus on the atypical presentation of melanoma in this population. Sentinel lymph node biopsy may provide useful prognostic information, although nodal involvement is less likely in the elderly due to age-related changes in lymphatic flow. Several clinical trials have supported the efficacy and better side effect profile of targeted melanoma therapies compared with chemotherapy. Additionally, topical and local treatment, including imiquimod and talimogene laherparepvec, are useful for older patients who cannot tolerate systemic therapy or surgical excision.

Summary

With a limited number of clinical trials in the elderly, and a steady increase in the incidence of disease, there is a need for development of better diagnostic and management strategies for older patients with melanoma. Elderly patients are underrepresented in clinical trials, and trial outcomes from younger patients may not be directly applicable to an older population. This population requires personalized care and consideration of toxic adverse effects on quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD [available from: https://seer.cancer.gov/csr/1975_2016/. Accessed 26 Aug 2020.

  2. Bulliard JL, Cox B. Cutaneous malignant melanoma in New Zealand: trends by anatomical site, 1969-1993. Int J Epidemiol. 2000;29(3):416–23.

    CAS  PubMed  Google Scholar 

  3. Marrett LD, Nguyen HL, Armstrong BK. Trends in the incidence of cutaneous malignant melanoma in New South Wales, 1983-1996. Int J Cancer. 2001;92(3):457–62.

    CAS  PubMed  Google Scholar 

  4. Gaudette LA, Gao RN. Changing trends in melanoma incidence and mortality. Health Rep. 1998;10(2):29–41 (Eng); 33–46 (Fre).

    CAS  PubMed  Google Scholar 

  5. Chang CK, Jacobs IA, Vizgirda VM, Salti GI. Melanoma in the elderly patient. Arch Surg. 2003;138(10):1135–8.

    CAS  PubMed  Google Scholar 

  6. Rees MJ, Liao H, Spillane J, Speakman D, McCormack C, Donahoe S, et al. Melanoma in the very elderly, management in patients 85years of age and over. J Geriatr Oncol. 2018;9(5):488–93.

    PubMed  Google Scholar 

  7. Ciocan D, Barbe C, Aubin F, Granel-Brocard F, Lipsker D, Velten M, et al. Distinctive features of melanoma and its management in elderly patients: a population-based study in France. JAMA Dermatol. 2013;149(10):1150–7.

    PubMed  Google Scholar 

  8. Lasithiotakis K, Leiter U, Meier F, Eigentler T, Metzler G, Moehrle M, et al. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer. 2008;112(8):1795–804.

    PubMed  Google Scholar 

  9. Macdonald JB, Dueck AC, Gray RJ, Wasif N, Swanson DL, Sekulic A, et al. Malignant melanoma in the elderly: different regional disease and poorer prognosis. J Cancer. 2011;2:538–43.

    PubMed  PubMed Central  Google Scholar 

  10. Azzola MF, Shaw HM, Thompson JF, Soong SJ, Scolyer RA, Watson GF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97(6):1488–98.

    PubMed  Google Scholar 

  11. Attis MG, Vollmer RT. Mitotic rate in melanoma: a reexamination. Am J Clin Pathol. 2007;127(3):380–4.

    PubMed  Google Scholar 

  12. Pan WR, Suami H, Taylor GI. Senile changes in human lymph nodes. Lymphat Res Biol. 2008;6(2):77–83.

    PubMed  Google Scholar 

  13. Tsai S, Balch C, Lange J. Epidemiology and treatment of melanoma in elderly patients. Nat Rev Clin Oncol. 2010;7(3):148–52.

    PubMed  Google Scholar 

  14. Tsao H, Bevona C, Goggins W, Quinn T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol. 2003;139(3):282–8.

    PubMed  Google Scholar 

  15. de Vries E, Nijsten TE, Visser O, Bastiaannet E, van Hattem S, Janssen-Heijnen ML, et al. Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol. 2008;19(3):583–9.

    PubMed  Google Scholar 

  16. Demierre MF, Chung C, Miller DR, Geller AC. Early detection of thick melanomas in the United States: beware of the nodular subtype. Arch Dermatol. 2005;141(6):745–50.

    PubMed  Google Scholar 

  17. Kelly JW. Melanoma in the elderly--a neglected public health challenge. Med J Aust. 1998;169(8):403–4.

    CAS  PubMed  Google Scholar 

  18. Hanrahan PF, Hersey P, D'Este CA. Factors involved in presentation of older people with thick melanoma. Med J Aust. 1998;169(8):410–4.

    CAS  PubMed  Google Scholar 

  19. Hanrahan PF, Hersey P, Menzies SW, Watson AB, D'Este CA. Examination of the ability of people to identify early changes of melanoma in computer-altered pigmented skin lesions. Arch Dermatol. 1997;133(3):301–11.

    CAS  PubMed  Google Scholar 

  20. Kelly JW, Chamberlain AJ, Staples MP, McAvoy B. Nodular melanoma. No longer as simple as ABC. Aust Fam Physician. 2003;32(9):706–9.

    PubMed  Google Scholar 

  21. Tio D, van der Woude J, Prinsen CAC, Jansma EP, Hoekzema R, van Montfrans C. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures. J Eur Acad Dermatol Venereol. 2017;31(4):616–24.

    CAS  PubMed  Google Scholar 

  22. Wolf IH, Cerroni L, Kodama K, Kerl H. Treatment of Lentigo Maligna (melanoma in situ) with the immune response modifier Imiquimod. Arch Dermatol. 2005;141(4):510–4.

    CAS  PubMed  Google Scholar 

  23. Ray CM, Kluk M, Grin CM, Grant-Kels JM. Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. Int J Dermatol. 2005;44(5):428–34.

    PubMed  Google Scholar 

  24. Sladden MJ, Balch C, Barzilai DA, et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev. 2009(4).

  25. Bolognia J, Schaffer J, Cerroni L. Dermatology. 4th edition ed. Amsterdam: Elsevier; 2017.

    Google Scholar 

  26. Testori A, Stanganelli I, Della Grazia L, Mahadavan L. Diagnosis of melanoma in the elderly and surgical implications. Surg Oncol. 2004;13(4):211–21.

    CAS  PubMed  Google Scholar 

  27. Coit DG, Thompson JA, Albertini MR, et al. Cutaneous melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(4):367–402.

  28. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–22.

    PubMed  PubMed Central  Google Scholar 

  30. Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757–67.

    PubMed  Google Scholar 

  31. •• Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer NH, Berking C, et al. Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J Clin Oncol. 2019;37(32):3000–8 Immediate complete lymph node dissection in melanoma patients with positive sentinel lymph nodes is not superior to observation in regards to overall survival, distant metastasis free survival and relapse free survival and thus is not recommended.

    CAS  PubMed  Google Scholar 

  32. Bilimoria KY, Balch CM, Wayne JD, Chang DC, Palis BE, Dy SM, et al. Health care system and socioeconomic factors associated with variance in use of sentinel lymph node biopsy for melanoma in the United States. J Clin Oncol. 2009;27(11):1857–63.

    PubMed  Google Scholar 

  33. Sabel MS, Kozminski D, Griffith K, Chang AE, Johnson TM, Wong S. Sentinel lymph node biopsy use among melanoma patients 75 years of age and older. Ann Surg Oncol. 2015;22(7):2112–9.

    PubMed  Google Scholar 

  34. Shah DR, Yang AD, Maverakis E, Martinez SR. Sentinel lymph node evaluation among elderly melanoma patients: missed opportunities? J Clin Oncol. 2012;30(15_suppl):e19001-e.

    Google Scholar 

  35. Shah DR, Yang AD, Maverakis E, Martinez SR. Age-related disparities in use of completion lymphadenectomy for melanoma sentinel lymph node metastasis. J Surg Res. 2013;185(1):240–4.

    PubMed  Google Scholar 

  36. Bilimoria KY, Balch CM, Bentrem DJ, Talamonti MS, Ko CY, Lange JR, et al. Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol. 2008;15(6):1566–76.

    PubMed  Google Scholar 

  37. •• Orloff M. Melanoma immunotherapy in the elderly. Curr Oncol Rep. 2018;20(2):20 Immunotherapy has shown great promise for management of melanoma, and there is growing data in support of using these agents in the elderly population. A personalized approach is recommended for use of immune checkpoint inhibitors in this population.

    PubMed  Google Scholar 

  38. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98–106.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Hurez V, Padron AS, Svatek RS, Curiel TJ. Considerations for successful cancer immunotherapy in aged hosts. Clin Exp Immunol. 2017;187(1):53–63.

    CAS  PubMed  Google Scholar 

  40. Mian I, Yang M, Zhao H, Shah M, Diab A, Shannon V, et al. Immune-related adverse events and survival in elderly patients with melanoma treated with ipilimumab. J Clin Oncol. 2016;34(15_suppl):3047.

    Google Scholar 

  41. Friedman CF, Horvat TZ, Minehart J, Panageas K, Callahan MK, Chapman PB, et al. Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+). J Clin Oncol. 2016;34(15_suppl):10009.

    Google Scholar 

  42. Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. • FDA. FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations 2018 [Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-and-binimetinib-combination-unresectable-or-metastatic-melanoma-braf. Accessed 26 Aug 2020. The Food and Drug Administration approved the use of encorafenib and binimetinib combination therapy for unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

  44. Liu W, Kelly JW, Trivett M, Murray WK, Dowling JP, Wolfe R, et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol. 2007;127(4):900–5.

    CAS  PubMed  Google Scholar 

  45. Shinozaki M, Fujimoto A, Morton DL, Hoon DS. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res. 2004;10(5):1753–7.

    CAS  PubMed  Google Scholar 

  46. Bauer J, Büttner P, Murali R, Okamoto I, Kolaitis NA, Landi MT, et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res. 2011;24(2):345–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15(4):436–44.

    CAS  PubMed  Google Scholar 

  48. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30.

    CAS  PubMed  Google Scholar 

  50. Ma C, Armstrong AW. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. J Dermatol Treat. 2014;25(5):401–8.

    Google Scholar 

  51. Hunter CP, Johnson KA, Muss HB. Cancer in the elderly. Boca Raton, Florida, USA: Taylor & Francis Group; 2000.

  52. Tarhini AA, Kirkwood JM. Clinical and immunologic basis of interferon therapy in melanoma. Ann N Y Acad Sci. 2009;1182:47–57.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19(9):2370–80.

    CAS  PubMed  Google Scholar 

  54. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7–17.

    CAS  PubMed  Google Scholar 

  55. Garbe C, Radny P, Linse R, Dummer R, Gutzmer R, Ulrich J, et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol. 2008;19(6):1195–201.

    CAS  PubMed  Google Scholar 

  56. Grob JJ, Dreno B, de la Salmoniere P, Delaunay M, Cupissol D, Guillot B, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998;351(9120):1905–10.

    CAS  PubMed  Google Scholar 

  57. Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 1998;16(4):1425–9.

    CAS  PubMed  Google Scholar 

  58. Wheatley K, Ives N, Eggermont A, Kirkwood J, Cascinelli N, Markovic SN, et al. Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. J Clin Oncol. 2007;25(18_suppl):8526.

    Google Scholar 

  59. Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dréno B, et al. Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma. Cancer. 2008;112(5):982–94.

    CAS  PubMed  Google Scholar 

  60. Broman KK, Zager JS. An evaluation of talimogene laherparepvec for the treatment of melanoma. Expert Opin Biol Ther. 2020;20(1):9–14.

    CAS  PubMed  Google Scholar 

  61. • Haitz K, Khosravi H, Lin JY, Menge T, Nambudiri VE. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma. J Am Acad Dermatol. 2020;83(1):189–96. A number of clinical trials have demonstrated the efficacy of intralesional treatment of advanced melanoma with T-VEC, and this oncolytic virotherapy is a promising local melanoma therapy.

  62. Rehman H, Silk AW, Kane MP, Kaufman HL. Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer. 2016;4:53.

    PubMed  PubMed Central  Google Scholar 

  63. Naqash AR, Stroud G, Collichio FA, Muzaffar M, Sharma N, Walker P. Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab. Acta Oncol. 2017;56(10):1327–30.

    PubMed  Google Scholar 

  64. Schvartsman G, Perez K, Flynn JE, Myers JN, Tawbi H. Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma. J Immunother Cancer. 2017;5:45.

    PubMed  PubMed Central  Google Scholar 

  65. Blackmon JT, Stratton MS, Kwak Y, Pavlidakey PG, Slominski AT, McKee SB, et al. Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec. JAAD Case Rep. 2017;3(4):280–3.

    PubMed  PubMed Central  Google Scholar 

  66. Hegde UP, Chakraborty N, Kerr P, Grant-Kels JM. Melanoma in the elderly patient: relevance of the aging immune system. Clin Dermatol. 2009;27(6):537–44.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Dermatology, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, 3411 Wayne Avenue, Second Floor, Bronx, NY, 10467, USA

    Kayla M. Babbush & Shadi Damanpour

Authors
  1. Kayla M. Babbush
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shadi Damanpour
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shadi Damanpour.

Ethics declarations

Conflict of Interest

The authors have no disclosures to report.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Dermatology and Wound Care

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Babbush, K.M., Damanpour, S. Melanoma Diagnosis and Treatment in the Elderly. Curr Geri Rep 9, 199–205 (2020). https://doi.org/10.1007/s13670-020-00330-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13670-020-00330-w

Keywords

Search

Navigation